Huntington's disease: a clinical review

被引:649
作者
Roos, Raymund A. C. [1 ]
机构
[1] LUMC, Dept Neurol, NL-2300 RC Leiden, Netherlands
来源
ORPHANET JOURNAL OF RARE DISEASES | 2010年 / 5卷
关键词
GENE CARRIERS; REPEAT; MODELS;
D O I
10.1186/1750-1172-5-40
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system characterized by unwanted choreatic movements, behavioral and psychiatric disturbances and dementia. Prevalence in the Caucasian population is estimated at 1/10,000-1/20,000. Mean age at onset of symptoms is 30-50 years. In some cases symptoms start before the age of 20 years with behavior disturbances and learning difficulties at school (Juvenile Huntington's disease; JHD). The classic sign is chorea that gradually spreads to all muscles. All psychomotor processes become severely retarded. Patients experience psychiatric symptoms and cognitive decline. HD is an autosomal dominant inherited disease caused by an elongated CAG repeat (36 repeats or more) on the short arm of chromosome 4p16.3 in the Huntingtine gene. The longer the CAG repeat, the earlier the onset of disease. In cases of JHD the repeat often exceeds 55. Diagnosis is based on clinical symptoms and signs in an individual with a parent with proven HD, and is confirmed by DNA determination. Pre-manifest diagnosis should only be performed by multidisciplinary teams in healthy at-risk adult individuals who want to know whether they carry the mutation or not. Differential diagnoses include other causes of chorea including general internal disorders or iatrogenic disorders. Phenocopies (clinically diagnosed cases of HD without the genetic mutation) are observed. Prenatal diagnosis is possible by chorionic villus sampling or amniocentesis. Preimplantation diagnosis with in vitro fertilization is offered in several countries. There is no cure. Management should be multidisciplinary and is based on treating symptoms with a view to improving quality of life. Chorea is treated with dopamine receptor blocking or depleting agents. Medication and non-medical care for depression and aggressive behavior may be required. The progression of the disease leads to a complete dependency in daily life, which results in patients requiring full-time care, and finally death. The most common cause of death is pneumonia, followed by suicide.
引用
收藏
页数:8
相关论文
共 31 条
  • [1] [Anonymous], OMIM ONLINE MENDELIA
  • [2] ARNULF I, 2008, ARCH NEUROL-CHICAGO, V65, P1478
  • [3] Weight loss in Huntington disease increases with higher CAG repeat number
    Aziz, N. A.
    van der Burg, J. M. M.
    Landwehrmeyer, G. B.
    Brundin, P.
    Stijnen, T.
    Roos, R. A. C.
    [J]. NEUROLOGY, 2008, 71 (19) : 1506 - 1513
  • [4] Aziz NA, 2007, REV NEUROSCIENCE, V18, P223
  • [5] A systematic review of the treatment studies in Huntington's disease since 1990
    Bonelli, Raphael M.
    Hofmann, Peter
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (02) : 141 - 153
  • [6] Pharmacological management of Huntington's disease: An evidence-based review
    Bonelli, Raphael M.
    Wenning, Gregor K.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (21) : 2701 - 2720
  • [7] BROHOLM J, 1994, NEUROLOGY, V44, P1533
  • [8] Bruyn G., 1968, HDB CLINICAL NEUROLO, V6, P298
  • [9] Craufurd D, 2001, NEUROPSY NEUROPSY BE, V14, P219
  • [10] The complexity of reproductive decision-making in asymptomatic carriers of the Huntington mutation
    Decruyenaere, Marleen
    Evers-Kiebooms, Gerry
    Boogaerts, Andrea
    Philippe, Kristien
    Demyttenaere, Koen
    Dom, Rene
    Vandenberghe, Wim
    Fryns, Jean-Pierre
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2007, 15 (04) : 453 - 462